Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Novartis reported $4.72B in EBITDA for its fiscal quarter ending in March of 2023.

Ebitda Change
Alcon AG ALC:SW USD 572M 273M
Almirall SA ALM:SM EUR 77.96M 19.34M
Amgen AMGN:US USD 3B 42M
AstraZeneca AZN:LN USD 4.28B 965M
Bayer BAYN:GR EUR 4.47B 1.31B
Biogen BIIB:US USD 686.7M 312.1M
Bristol-Myers Squibb BMY:US USD 5.43B 772M
Eli Lilly LLY:US USD 1.96B 528.3M
Fresenius FRE:GR EUR 1.61B 509M
Gilead Sciences GILD:US USD 2.24B 456M
GlaxoSmithKline GSK:LN GBP 2.56B 960M
Hikma Pharmaceutical HIK:LN USD 350M 1000K
J&J JNJ:US USD 9B 934.8M
Lonza Group LONN:SW CHF 1.21B 220M
Novartis NOVN:VX USD 4.72B 217M
Novartis NVS:US USD 4.72B 217M
Orion ORNBV:FH EUR 67.7M 14.6M
Pfizer PFE:US USD 8.01B 683M
Philips PHIA:NA EUR 596M 333M
Recordati REC:IM EUR 212.55M 72.5M
Regeneron Pharmaceuticals REGN:US USD 1.1B 195.4M
Roche Holding ROG:VX CHF 10.43B 3B